Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

Amgen (NASDAQ:AMGN) declares $2.38/share quarterly dividend, 5.8% increase from prior dividend of $2.25. Forward yield 3.45% ...

Amgen appointed Naveen Gullapalli, former Novartis executive, as Managing Director of Amgen India. Gullapalli will lead Amgen ...

The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard ...

Gullapalli will oversee the Amgen India Technology and Innovation hub, leveraging his extensive expertise in global ...

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025, to all stockholders of ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

Pharmaceutical and biotech businesses were enthusiastic about the UPC before the court opened, but so far there has only been ...

The board of Amgen boosted its quarter dividend by almost 6%. The Thousand Oaks, Calif.-based biotechnology company said Tuesday that it raised its dividend to $2.38 per share for the first quarter, ...

As Donald J. Trump gradually fills out his cabinet, the President-elect’s latest pick could bode well for biopharma business ...

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...